Move Starts To Strip Anticancer Drug Regulation From FDA After New Charges It Is Delaying INDs
In Brief: NCI Needs To Move Quicker On Funding Jot New Leads, Rauscher Says; Harley Dirks Quits
Frederick RFP Held Up; NCI Probably Will Reject Any Further Delay
Moloney Convinces Most NCAB Members Of Virus Program Value, Shubik Only Dissenter
King Tells Centers To Concentrate On Project Grants
First Lady Helps Dedicate New MDA Facilities
Disease Oriented Programs Must Be Coordinated: Rabson
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- FDA’s OCE publishes three final guidances to increase clinical trial enrollment
